MAPT and Alzheimer disease: Furthermore, p‐tau217 outperformed all other plasma biomarkers in predicting AD pathology and cognitive decline,22, 23 and strongly correlated with amyloid and tau PET, Braak stages, and neuropathologically defined AD.22, 25